Vena Medical, a leading developer of cutting-edge neurovascular devices, recently announced the successful treatment of the first five patients in the world using the Vena BDAC™ at London Health Sciences Centre (LHSC) University Hospital and The Ottawa Hospital (TOH).
Canada is the first to benefit from the Vena BDAC™ technology developed right in the patient’s backyard for those requiring mechanical thrombectomy during ischemic stroke treatment.
Thrombectomy, a minimally invasive procedure to remove a blood clot, is now standard of care treatment for patients with an acute ischemic stroke (AIS) secondary to a Large Vessel Occlusion (LVO). There are several techniques available, all with the objective of restoring blood flow as quickly as possible. The Vena BDAC™ combines the balloon guide catheters and distal access catheters that are currently used in thrombectomy to remove clots from the brains of stroke victims. Combining these two devices allows the clinician to get the balloon much closer to the clot, which is shown to improve key metrics like First Pass Success Rate, allowing removal of the clot on the first try and leading to significantly better patient outcomes. This also reduces the number of devices to treat each patient and therefore the cost of the procedure.
Vena Medical is an OBIO® member, an Early Adopter Health Network (EAHN™) company and presented at the OBIO Investment Summit.